Speakers
Jianwei Xuan, PhD, China Southern Medical University, School of Pharmaceutical Sciences, Guangzhou, China; C. Daniel Mullins, PhD, University of Maryland School of Medicine, Baltimore, MD, United States
Separate registration required.
This introductory course will describe the methods and critical steps involved to estimate the health insurance reimbursement budget impact when a novel healthcare technology will be incorporated into the reimbursement list. The course will present 6 critical steps for estimating budget impact: (1) estimating the target population; (2) selecting a time horizon; (3) identifying current and projected treatment mix; (4) estimating current and future drug costs; (5) estimating change in disease-related costs; and (6) estimating and presenting changes in annual budget impact and health outcomes. Along the 6 steps, critical scenario analysis planning and real world application case will also be illustrated. Both static and dynamic methods for estimating the budget and health impact of adding a new drug to a health plan formulary will be presented. These critical steps will be illustrated using actual budget impact models and AI application in BIA model will also be discussed and explored. This course is designed for those with some experience with pharmacoeconomic analysis.
Code
04